This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

milvexian
Medical Information

Mechanism of Action

Last Updated: 11/18/2026

SUMMARY

  • Milvexian is an oral investigational factor XIa inhibitor being studied for prevention and treatment of major thrombotic conditions.
  • Milvexian is a direct, reversible, orally active, small molecule that inhibits the active form of factor XI (FXIa) with high affinity and selectivity.1,2
  • A clinical study found that administration of milvexian resulted in a concentration-related prolongation of activated partial thromboplastin time (aPTT) and a decrease in FXI clotting activity.3
  • A study evaluated the pharmacodynamic effect of milvexian on plasma clot formation and stability in an in vitro study of 5 healthy individuals.4

BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION

Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.

To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.

To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.

MECHANISM OF ACTION

Milvexian is a direct, reversible, orally active, small molecule that inhibits the active form of factor XI (FXIa) with high affinity and selectivity.1 In studies, milvexian extended the aPTT in a dose-dependent way and did not impact the prothrombin time (PT).3,5In general, the timing of aPTT prolongation aligned with the plasma milvexian concentration-time profile.3,5,6

Clinical Study of Milvexian in Healthy Human Subjects

Perera et al (2022)3 conducted a two-part, randomized, double-blind, placebo-controlled, sequential single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian in healthy subjects. Subjects in the SAD panels received milvexian at doses of 4 mg, 20 mg, 60 mg, 200 mg, 300 mg, and 500 mg whereas subjects in the MAD panels received milvexian at doses of 5 mg, 20 mg, 70 mg, 200 mg, and 500 mg.

  • After administration of milvexian, there was a concentration-related prolongation of aPTT and reduction in FXI clotting activity.
  • At any given point of time, prothrombin time was not increased.

In Vitro Study

Holle et al (2021)4 evaluated the pharmacodynamic effect of milvexian on plasma clot formation and stability in an in vitro study of 5 healthy individuals. Clot formation in normal pooled plasma and plasma was conducted with tissue factor, phospholipids, calcium chloride, and varying concentrations of milvexian or buffer. Fibrinolysis experiments included tissue plasminogen activator. Reactions were monitored by turbidity, and descriptive parameters were analyzed to determine half-maximal effect concentrations.

  • Milvexian delayed clot formation, reduced clot formation rate in a dose-dependent manner, and decreased final clot turbidity.
  • Clot lysis time was shortened, indicating less resistance to fibrinolysis.
  • Effects were observed at pharmacologically-relevant concentrations achieved through oral administration in humans.
  • Half-maximal effects on clot formation and stability were seen at 3-4 µg/mL milvexian.
  • Anticoagulant effects occurred at levels below those associated with bleeding risk in FXI-deficient patients.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, Derwent® (and/or other resources, including internal/external databases) was conducted on 20 July 2026.

 

References

1 Perera V, Abelian G, Li D, et al. Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment. Clin Pharmacokinet. 2022;61(10):1405-1416.  
2 Wong PC, Crain EJ, Bozarth JM, et al. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits. J Thromb Haemost. 2022;20(2):399-408.  
3 Perera V, Wang Z, Luettgen J, et al. First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022;15(2):330-342.  
4 Holle LA, Luettgen JM, Wolberg AS. Factor XIa inhibitor milvexian (BMS-986177/JNJ 70033093) suppresses plasma clot formation and reduces resistance to fibrinolysis in vitro [abstract]. Res Pract Thromb Haemost. 2021;5(Suppl. 2):e12589. Abstract PB0044.  
5 Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161-2172.  
6 Perera V, Wang Z, Lubin S, et al. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Sci Rep. 2022;12(1):5165.  

Would you like to clear and leave your conversation? Message history will be lost.